

02 Sep 2024 | Analysis

Pink Sheet Podcast: New US FDA Developments In AI Regulation

by Pink Sheet Team

Pink Sheet reporter and editors discuss new developments in the FDA's plans to regulate artificial intelligence and drugs associated with it, including a new AI Council within CDER, as well as some of the unanswered questions about AI in drug development.

Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter and Interim Editor-in-Chief Nielsen Hobbs discuss the impact of some recent US Food and Drug Administration news on artificial intelligence regulation, including the creation of a new AI Council in the Center for Drug Evaluation and Research (:39). They also discuss industry questions about inspections of AI-related products and other lingering regulatory uncertainties (5:07).

Click here to explore this interactive content online

More On These Topics From The Pink Sheet

- Artificial Intelligence: CDER's New Council Takes Charge Of Oversight, Coordination
- AI In Drug Development: Regulatory Clarity Needed On Inspections, Human Role

This and other podcasts are available on the *Pink Sheet podcast page*, as well as the *Citeline* channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.